Diagnosis and management of interstitial lung disease with concomitant lung cancer in Italy: Results from the ICARO clinician survey - PubMed
3 days ago
- #Lung Cancer
- #Clinical Survey
- #Interstitial Lung Disease
- The survey shows substantial variability in managing lung cancer in patients with interstitial lung disease in Italy, driven by concerns over ILD progression and treatment toxicity.
- An ILD multidisciplinary team was available in 71.1% of the centers, and 36.8% reported performing lung cancer diagnostic procedures 'always/often', with 81.6% concerned about ILD progression post-procedures.
- Most clinicians (73.7%) continued antifibrotic therapy during systemic cancer treatment, and 50% perceived combined chemotherapy plus immune checkpoint inhibitors as the highest-risk regimen.
- Neoadjuvant immunotherapy in stage II-IIIa NSCLC was approached with hesitancy by 52.6% of respondents, and 21.1% reported frequent severe toxicity from radiotherapy.
- The study highlights an urgent need for prospective research to define safety and efficacy of combined therapies and to develop evidence-based guidelines.